CJC-1295 (No DAC), GHRP-6

CJC-1295 (No DAC), GHRP-6 – Benefits & Side Effects

CJC-1295 (No DAC), GHRP-6 – Protocol

CJC-1295 (No DAC), GHRP-6 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

CJC-1295 (No DAC), GHRP-6 – Identification

Common Name(s): CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29), Modified GRF (1-29), GRF (1-29) analog, tetra-substituted GRF (1-29), CJC1295 pulsatile formulation; GHRP-6, Growth Hormone Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide, Growth Hormone Releasing Peptide, Hexapeptide-2, His(1)-Lys(6)-GHRP, SKF-110679, U 75799E; Blend Designation: CJC-1295 (No DAC)/GHRP-6 blend, CJC-1295/GHRP-6 combination, Mod GRF/GHRP-6 blend

CJC-1295 (No DAC) Chemical Specification:

• CAS Number: 446036-97-1

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3,367.9–3,369.1 Da (g/mol)

• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

• Short Code Notation: Modified GHRH(1-29)

• Sequence Length: 29 amino acids

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis

  • Functional Class: GHRH analog, growth hormone secretagogue, hormonal regulatory peptide

  • Structural Type: Linear polypeptide with four critical amino acid substitutions from naturally occurring GHRH(1-29)

• Key Structural Modifications:

  • Four amino acid substitutions: Positions 2 (D-Ala replacing Ala), 8, 15, and 27, designed to increase resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation

  • Absence of DAC: Unlike CJC-1295 with DAC, the "No DAC" variant lacks the drug affinity complex (maleimidopropionamide-lysine) that enables covalent binding to serum albumin

  • Half-life: Approximately 30 minutes due to absence of albumin-binding moiety, permitting rapid clearance and pulsatile GH secretion patterns

  • GH Release Profile: Pulsatile/acute stimulation mimicking natural GHRH action, rather than the sustained elevation characteristic of CJC-1295 with DAC

• Physical Form: Lyophilized white to off-white powder

• Solubility: Slightly soluble in water at physiological pH; reconstituted in appropriate buffers

• Storage Requirements: -20°C (or lower), protected from light and moisture, under inert atmosphere (nitrogen or argon)

GHRP-6 Chemical Specification:

• CAS Number: 87616-84-0

• Molecular Formula: C₄₆H₅₆N₁₂O₆

• Molecular Weight: 872.45–873.04 Da (g/mol)

• Amino Acid Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

• Sequence Notation (One-Letter): H-W-A-W-f-K-NH₂ (where lowercase f designates D-Phe, uppercase W designates D-Trp)

• IUPAC Nomenclature: L-Histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide

• Sequence Length: 6 amino acids (hexapeptide)

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis

  • Functional Class: Growth hormone secretagogue, ghrelin receptor agonist, met-enkephalin analog, hormonal regulatory peptide

  • Structural Type: Linear hexapeptide

• Key Structural Features:

  • D-amino acids: Two D-amino acids (D-Trp at position 2 and D-Phe at position 5) provide enhanced enzymatic stability and resistance to peptidase degradation compared to all-L-amino acid peptides

  • β-2-Naphthylalanine substitution: Although GHRP-6 contains standard tryptophan (not specialized naphthylalanine), structural studies note the importance of the tryptophan residues at positions 2 and 4 for receptor binding and biological potency

  • Amino-terminal histidine: N-terminal histidine (His1) residue distinguishes GHRP-6 from related hexapeptides such as GHRP-1 (lacking His1)

  • Development History: Synthetic hexapeptide developed in 1984 and reported as one of the first-generation GHRPs; preceded by GHRP-1 and followed by more potent analogs including GHRP-2 (1992) and hexarelin (modified GHRP-6 analog)

• Physical Form: Lyophilized powder or solution; various salt forms (free base, acetate, trifluoroacetate, dihydrochloride) utilized commercially

• Solubility: Slightly soluble in water; variable compatibility with organic solvents; stable in reconstituted aqueous solutions with appropriate buffers

• Storage Requirements: -20°C or below (lyophilized), 2–8°C (reconstituted solutions, up to 21 days with recommended carrier protein at 0.1% HSA or BSA to prevent aggregation)

Blend Specifications:

• Composition Ratio: Supplier-dependent; common ratios include 1:1 (w/w equivalent mass) or 1:1 (molar equivalent). Example formulation: CJC-1295 (No DAC) 5 mg + GHRP-6 5 mg = 10 mg total blend

• Combined Molecular Weight: Approximately 4,241–4,243 Da (sum of both peptides)

• Physical Form: Lyophilized blend or reconstituted liquid formulation

• Storage: -20°C or lower, protected from light and moisture under inert atmosphere

FDA and Chemical Registry Information:

• CJC-1295 (No DAC): FDA UNII 62RC32V9N7; PubChem CID 91976842

• GHRP-6: FDA UNII 4H7N4I6X6A; PubChem CID 9919153

Known Synonyms, Abbreviations, and Literature References:

• CJC-1295 (No DAC): GRF(1-29) analog, GHRH(1-29) modified, Modified GHRH (1-29), Tetra-substituted GRF, CJC-1295 (pulsatile formulation), CJC1295 Without DAC, MOD-GRF (1-29), Mod GRF, CJC-1295 (free), GRF(1-29) DPP-4 resistant analog

• GHRP-6: Pralmorelin (INN designation for certain GHRP analogs, though GHRP-6 predates this nomenclature), [His1, Lys6]-GHRP, Growth Hormone-Releasing Hexapeptide, Hexapeptide-2, Melanostatine-2, HWAWFK-NH₂, SKF-110679, U 75799E, GHRP 6, GH Releasing Peptide 6, GHRP-6 acetate (salt form), GHRP-6 dihydrochloride (salt form)

• Blend Designations: CJC-1295 (No DAC)/GHRP-6 blend, Mod GRF/GHRP-6 combination, CJC-1295 and GHRP-6 blend, CJC-1295 (No DAC), GHRP-6 peptide blend

Database Links:

• CJC-1295 (No DAC):

  • PubChem: CID 91976842 – Full chemical structure, molecular properties, synonyms

  • ChemicalBook: CB68571045 – Supplier database, chemical specifications, safety information

  • NCBI PubMed: Extensive literature starting with Teichman et al. (2006) PMID 16352683 and PMID 16822960

• GHRP-6:

  • PubChem: CID 9919153 – Hexapeptide reference structure, molecular data

  • ChemicalBook: CB8421540 – Comprehensive database with suppliers and specifications

  • DrugBank: DB18238 – Clinical and pharmacological information

  • NCBI PubMed: Literature spanning 1984–present, including foundational studies (PMID 7734029, PMID 15699539, PMID 27200188, PMID 12567389)

Supplier Identification Variation:

CJC-1295 (No DAC) maintains consistent chemical identity across suppliers with negligible variation; primary differences involve purity specification (95–99.9%) and buffer composition. GHRP-6 exhibits consistency in core chemical structure but varies significantly by salt form (free base, acetate, dihydrochloride, trifluoroacetate) with corresponding nominal molecular weight adjustments due to counter-ion mass. When supplied as a blend, the ratio of CJC-1295:GHRP-6 varies by commercial source; researchers requiring precise stoichiometric proportions should verify component masses with individual suppliers. The blend itself lacks independent chemical database identifiers and is referenced exclusively by component CAS numbers or peptide designations.

CJC-1295 (No DAC), GHRP-6 – Research

Study: Growth Hormone Secretion After Administration of GHRP-6 Combined with GHRH
Benefits: Restores "youthful" hormone levels, creates a massive growth signal, and dramatically increases hunger.
Link: https://pubmed.ncbi.nlm.nih.gov/7734029/
Summary: As people get older, their natural growth hormone levels drop, which is why skin sags and muscles shrink. This study looked at what happens when you give GHRP-6 along with a GHRH (like CJC-1295) to older adults. The result was a "synergistic" explosion of growth hormone—meaning 1+1 didn't equal 2, it equaled 10. The combination restored hormone secretions to levels seen in young adults. This is huge because it suggests that the pituitary gland isn't broken in older people; it just needs a louder signal. For younger users, this same synergy creates a powerful anabolic (growth) environment. The study proves that combining these two types of peptides is far more effective than using either one alone, making it a top choice for maximizing physical performance and recovery.

Study: The Synergistic Effects of GHRP-6 and GRF on Growth Hormone Release
Benefits: Activates two separate systems for maximum effect, protects heart cells, and speeds up injury repair.
Link: https://pubmed.ncbi.nlm.nih.gov/2541999/
Summary: Scientists wanted to know if GHRP-6 and GHRH (CJC-1295) competed with each other or helped each other. They found that they work on completely different receptors—like using two different keys to unlock the same treasure chest. GHRP-6 doesn't just release hormone; it also protects cells. Research shows it has a direct protective effect on heart muscle cells and can help tissues survive when they aren't getting enough oxygen. When mixed with CJC-1295, the result is a sustained, high-level release of Growth Hormone that lasts for hours. This "pulse" of hormone is exactly what the body needs to repair torn muscles, heal ligaments, and recover from intense stress. It essentially turns the body's repair dial up to maximum.

Study: Effect of Combined Administration of GHRH and GHRP-6 in Obesity
Benefits: Overcomes the body's resistance to weight loss, stimulates intense appetite for bulking, and improves body composition.
Link: https://pubmed.ncbi.nlm.nih.gov/7783658/
Summary: Usually, people who are carrying extra weight have trouble releasing growth hormone, which makes it even harder to lose fat and build muscle. This study found that the GHRP-6 and CJC-1295 combo was strong enough to break through this blockade. It forced the body to release GH even in obese patients who normally wouldn't. A key side effect noted in research is extreme hunger—GHRP-6 mimics a hormone called ghrelin that screams "EAT NOW" to the brain. While this might sound bad for dieting, for an athlete trying to "bulk up" and pack on muscle mass, it's a superpower. It allows them to eat the massive amount of calories needed to grow, while the high GH levels ensure those calories turn into muscle, not fat. This makes it the ultimate "bulking" stack according to the research data.

CJC-1295 (No DAC), GHRP-6 – Research Links